Who is the “reasonable investor”? von Tuttle, Jonathan R., Kaplan, Matthew E., Pedersen, Benjamin R.

Volltext

SEC enforcement actions getting up close and personal von Kaplan, Matthew E, Paley, Alan H, Tuttle, Jonathan R

Volltext

SEC announces new policy concerning financial penalties: guidelines provide companies with road map on how to avoid or limit penalties von Tuttle, Jonathan R, Yannett, Bruce E, White, Mary Jo

Volltext

The first 48 hours: no board missteps: avoiding catastrophe in the early stages of an internal investigation von Tuttle, Jonathan R

Volltext

SEC's Division of Enforcement Year-End Results Provide Insight into Record-Breaking Year von Brockmeyer, Kara, Ceresney, Andrew J, June, Arian M, Kaplan, Robert B, Riewe, Julie M, Snyder, Kristin A, Tuttle, Jonathan R, White, Mary Jo

Volltext

Supreme Court Clarifies Scope of Dodd-Frank's Whistleblower Protections von White, Mary Jo, Brockmeyer, Kara, Ceresney, Andrew J, Hamid, Jyotin, Hogan, Mary Beth, Kaplan, Robert B, Riewe, Julie M, Tuttle, Jonathan R, Johnson, Ada Fernandez, June, Arian M, Kusmin, Ryan M

Volltext

Court finds no duty to disclose Wells Notices von Tuttle, Jonathan R, Kaplan, Matthew E, Laporte, Margot

Volltext

The first 48 hours: No board missteps von Tuttle, Jonathan R

Volltext

The Eleventh Circuit casts doubts on "obey the law" injunctions von Berger, Paul R, Smith, Colby A, Tuttle, Jonathan R, Johnson, Ada Fernandez

Volltext

Touch point and attribute tracking system and process von Gorski, Mark C, Hanley, Kevin E, Kruse, Vicki A, Tuttle, Jonathan R

Volltext bestellen

Touch point and attribute tracking system and process von KRUSE VICKI A, TUTTLE JONATHAN R, HANLEY KEVIN E, GORSKI MARK C

Volltext bestellen

Touch point and attribute tracking system and process von KRUSE VICKI A, TUTTLE JONATHAN R, HANLEY KEVIN E, GORSKI MARK C

Volltext bestellen

Kidney Disease and Increased Mortality Risk in Type 2 Diabetes von AFKARIAN, Maryam, SACHS, Michael C, KESTENBAUM, Bryan, HIRSCH, Irl B, TUTTLE, Katherine R, HIMMELFARB, Jonathan, DE BOER, Ian H

Volltext

Executive summary of the KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease: an update based on rapidly emerging new evidence von Rossing, Peter, Caramori, M Luiza, Chan, Juliana C N, Heerspink, Hiddo J L, Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D, Navaneethan, Sankar D, Olowu, Wasiu A, Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R, Wanner, Christoph, Wilkens, Katy G, Zoungas, Sophia, Craig, Jonathan C, Tunnicliffe, David J, Tonelli, Marcello A, Cheung, Michael, Earley, Amy, de Boer, Ian H

Volltext

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment von de Boer, Ian H., Caramori, M. Luiza, Chan, Juliana C.N., Heerspink, Hiddo J.L., Hurst, Clint, Khunti, Kamlesh, Liew, Adrian, Michos, Erin D., Navaneethan, Sankar D., Olowu, Wasiu A., Sadusky, Tami, Tandon, Nikhil, Tuttle, Katherine R., Wanner, Christoph, Wilkens, Katy G., Zoungas, Sophia, Lytvyn, Lyubov, Craig, Jonathan C., Tunnicliffe, David J., Howell, Martin, Tonelli, Marcello, Cheung, Michael, Earley, Amy, Rossing, Peter

Volltext

An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 von Owen, Dafydd R, Allerton, Charlotte M N, Anderson, Annaliesa S, Aschenbrenner, Lisa, Avery, Melissa, Berritt, Simon, Boras, Britton, Cardin, Rhonda D, Carlo, Anthony, Coffman, Karen J, Dantonio, Alyssa, Li, Di, Eng, Heather, Ferre, RoseAnn, Gajiwala, Ketan S, Gibson, Scott A, Greasley, Samantha E, Hurst, Brett L, Kadar, Eugene P, Kalgutkar, Amit S, Lee, Jack C, Lee, Jisun, Liu, Wei, Mason, Stephen W, Noell, Stephen, Novak, Jonathan J, Obach, R Scott, Ogilvie, Kevin, Patel, Nandini C, Pettersson, Martin, Rai, Devendra K, Reese, Matthew R, Sammons, Matthew F, Sathish, Jean G, Singh, Ravi Shankar P, Steppan, Claire M, Stewart, Al E, Tuttle, Jamison B, Updyke, Lawrence, Verhoest, Patrick R, Wei, Liuqing, Yang, Qingyi, Zhu, Yuao

Volltext

Highly efficient Cas9-mediated transcriptional programming von Chavez, Alejandro, Scheiman, Jonathan, Vora, Suhani, Pruitt, Benjamin W, Tuttle, Marcelle, P R Iyer, Eswar, Lin, Shuailiang, Kiani, Samira, Guzman, Christopher D, Wiegand, Daniel J, Ter-Ovanesyan, Dmitry, Braff, Jonathan L, Davidsohn, Noah, Housden, Benjamin E, Perrimon, Norbert, Weiss, Ron, Aach, John, Collins, James J, Church, George M

Volltext

Empagliflozin in Patients with Chronic Kidney Disease von Herrington, William G, Staplin, Natalie, Wanner, Christoph, Green, Jennifer B, Hauske, Sibylle J, Emberson, Jonathan R, Preiss, David, Judge, Parminder, Mayne, Kaitlin J, Ng, Sarah Y A, Sammons, Emily, Zhu, Doreen, Hill, Michael, Stevens, Will, Wallendszus, Karl, Brenner, Susanne, Cheung, Alfred K, Liu, Zhi-Hong, Li, Jing, Hooi, Lai Seong, Liu, Wen, Kadowaki, Takashi, Nangaku, Masaomi, Levin, Adeera, Cherney, David, Maggioni, Aldo P, Pontremoli, Roberto, Deo, Rajat, Goto, Shinya, Rossello, Xavier, Tuttle, Katherine R, Steubl, Dominik, Petrini, Michaela, Massey, Dan, Eilbracht, Jens, Brueckmann, Martina, Landray, Martin J, Baigent, Colin, Haynes, Richard

Volltext

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial von Tuttle, Katherine R, Brosius, 3rd, Frank C, Adler, Sharon G, Kretzler, Matthias, Mehta, Ravindra L, Tumlin, James A, Tanaka, Yoshiya, Haneda, Masakazu, Liu, Jiajun, Silk, Maria E, Cardillo, Tracy E, Duffin, Kevin L, Haas, Joseph V, Macias, William L, Nunes, Fabio P, Janes, Jonathan M

Volltext

New Therapies for Diabetic Kidney Disease von Himmelfarb, Jonathan, Tuttle, Katherine R

Volltext